Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18061342 | 1.00 | CA12 (0.33) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL30281150 | 0.72 | CA12 (0.39) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL29164396 | 0.66 | — | — | |
| Hydrochloric Acid SCHEMBL26921279 | 0.66 | AKT1 (0.51) | NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL26923029 | 0.66 | AKT1 (0.51) | NPC1RAB9A | |
| SCHEMBL23001706 | 0.66 | MAPT (0.43) | NPC1CASP3RAB9ASENP7 | |
| SCHEMBL2890927 | 0.65 | CA12 (0.55) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL2889879 | 0.65 | CA12 (0.39) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL29088214 | 0.63 | CA12 (0.53) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL21377774 | 0.63 | IDO1 (0.36) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264534-A1 | SYNTHESIS OF 3,4-BIS(4-NITRO-1,2,5-OXADIAZOL-3-YL)-1,2,5-OXADIAZOLE-N-OXIDE (DNTF) USING 3-CHLOROCARBOHYDROXYMOYL-4-NITRO-1,2,5-OXADIAZOLE | U.S. GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2016-09-15 | — | — | US | disclosed |
| US-9440936-B1 | Synthesis of 3,4-Bis(4-nitro-1,2,5-oxadizaol-3-yl)-1,2,5-oxadizaole-N-oxide (DNTF) using 3-chlorocarbohydroxymoyl-4-nitro-1,2,5-oxadizaole | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2016-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264534-A1 | SYNTHESIS OF 3,4-BIS(4-NITRO-1,2,5-OXADIAZOL-3-YL)-1,2,5-OXADIAZOLE-N-OXIDE (DNTF) USING 3-CHLOROCARBOHYDROXYMOYL-4-NITRO-1,2,5-OXADIAZOLE | NOX3, NOX1, NOS3 | CA12 3088/4885CA1 1384/4885CA2 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.